alison mcclean
@alison_mcclean
ID: 1204853008602783744
11-12-2019 19:58:42
42 Tweet
62 Followers
176 Following
Our newest paper led by the awesome alison mcclean in CMAJ Our original working title was "Failure to Launch" which is a great way coined by Mike Law to describe Canada's experience with #biosimilars so far. UBC Centre for Health Services and Policy Research Leslie Dan Faculty of Pharmacy
People living in 🇨🇦 still face barriers with equitable access to prescription drugs even when insured. Our Advisory Panel’s report outlines non-binding recommendations for Health Canada and PHAC on a potential pan-Canadian formulary. Read it here: cadth.info/3yq483L
New paper in ACR_Journals from alison mcclean Fiona Clement Mina T. Mike Law finds that mandatory switching policies were much more effective than new starting policies for increasing the use of biosimilar medications: pubmed.ncbi.nlm.nih.gov/36752358/
🧫 Anticancer #biosimilar use is rising but significant potential savings remain unrealized if formulary designs within fee-for-service Medicare Part B prioritize similarly effective but lower cost biosimilars ➡️ brnw.ch/21wCyqb alison mcclean Christine Lu
A new publication led by former @HealthPolicy_DPM fellow alison mcclean w/ Department of Population Medicine's #AnitaWagner & Christine Lu suggests that, while #biosimilar use is on the rise, the cost savings in #Medicare Part B remain unrealized. Read more in JCO Oncology Practice: buff.ly/3EJfamX
Potential cost savings in #Medicare Part B remain unrealized. Why, and possible solutions, in this new paper led by former Division of Health Policy and Insurance Research fellow alison mcclean w/Department of Population Medicine's #AnitaWagner, and Christine Lu:
With the plan for National Pharmacare slated to be introduced by March 1, please join us for the UBC Centre for Health Services and Policy Research conference, PharmaWhere?, on March 5. The early-bird deadline is 2 weeks away! Details and registration at chspr.ubc.ca/conference/ #pharmacare